HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vitamin D, Omega-3 No Help For Diabetics Against CKD, VITAL Data Show

Executive Summary

In latest study casting doubt on the nutrients' effect on chronic illness, researchers find vitamin D and fish oil ineffective in staving off type 2 diabetics' kidney failure. Editorial also published in JAMA says further research is needed to analyze the nutrients’ possible benefits to diabetics with chronic kidney disease.

You may also be interested in...



QHC For Vitamin D, Omega-3 Helping Prevent Autoimmune Conditions Has VITAL Data Support

Trial for 5.3 years with more than 25,000 consumers 50 and older pointing to a link between vitamin D and imegta-3s and reducing autoimmune disease isn’t the first with results from VITAL. “It's a big one that we've been watching for a number of years. And it's exciting, some exciting outcomes,” says CRN scientific and regulatory affairs exec Andrea Wong.

US Wellness Market In 2019: Amarin Wins, Loses On Supplements; Gottlieb Leaves With Consumer Health Flourish

Looking look back on US wellness market developments and events in 2019, HBW Insight finds a firm that doesn’t compete in the dietary supplement sector, Amarin, made a good bit of news that affected the industry during the year. We track news across the wellness space from the past year.

Study to examine vitamin D, omega-3 supplements

The Vitamin D and Omega-3 Trial - VITAL - will measure the supplements' preventive effects on cancer, heart disease and stroke in 20,000 participants, making it the largest randomized trial for vitamin D and omega-3 fatty acids. Brigham and Women's Hospital, an affiliate of Harvard Medical School, seeks to enroll women older than 65 and men older than 60 in the five-year study, which will include examinations of how the supplements affect cognitive function, vision disorders and diabetes, the hospital said. BWH Chief of Preventive Medicine JoAnn Manson said June 23 that "these low-cost supplements have the potential of tremendously reducing the burden of chronic disease." Previous economic analysis found omega-3 and vitamin D plus calcium supplementation could save billions in hospitalization costs (1"The Tan Sheet" Sept. 29, 2008, In Brief)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149405

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel